{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:16:56Z","timestamp":1791037016809,"version":"4.1.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,11,28]],"date-time":"2008-11-28T00:00:00Z","timestamp":1227830400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1186\/bcr2194","type":"journal-article","created":{"date-parts":[[2008,12,4]],"date-time":"2008-12-04T19:17:12Z","timestamp":1228418232000},"source":"Crossref","is-referenced-by-count":43,"title":["Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda"],"prefix":"10.1186","volume":"10","author":[{"given":"Bettina","family":"Meiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Barlow-Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Lobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christobel","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,11,28]]},"reference":[{"key":"2158_CR1","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1200\/JCO.2003.03.189","volume":"21","author":"American Society of Clinical Oncology","year":"2003","unstructured":"American Society of Clinical Oncology: American Society of Clinical Oncology Policy Statement. J Clin Oncol. 2003, 21: 2397-2406. 10.1200\/JCO.2003.03.189.","journal-title":"J Clin Oncol"},{"key":"2158_CR2","volume-title":"Guidelines on Familial Aspects of Cancer","author":"Australian Cancer Network","year":"1999","unstructured":"Australian Cancer Network: Guidelines on Familial Aspects of Cancer. 1999, Sydney: Australian Cancer Network"},{"key":"2158_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1023\/A:1011570302078","volume":"1","author":"G Mitchell","year":"2001","unstructured":"Mitchell G, Ardern-Jones A, Kissin Mchir M, Taylor R, Eeles RA, Mitchell G, Ardern-Jones A, Kissin Mchir M, Taylor R, Eeles RA: A paradox: Urgent BRCA genetic testing. Fam Cancer. 2001, 1: 25-29. 10.1023\/A:1011570302078.","journal-title":"Fam Cancer"},{"key":"2158_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10689-007-9147-7","volume":"7","author":"W Rubinstein","year":"2008","unstructured":"Rubinstein W: Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics. Fam Cancer. 2008, 7: 83-89. 10.1007\/s10689-007-9147-7.","journal-title":"Fam Cancer"},{"key":"2158_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10689-007-9167-3","volume":"7","author":"E Silva","year":"2008","unstructured":"Silva E: Genetic counselling and clinical management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations: Perspective of a surgical oncologist. Fam Cancer. 2008, 7: 91-95. 10.1007\/s10689-007-9167-3.","journal-title":"Fam Cancer"},{"key":"2158_CR6","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1038\/sj.onc.1209881","volume":"25","author":"S Domcheck","year":"2006","unstructured":"Domcheck S, Weber B: Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene. 2006, 25: 5825-5831. 10.1038\/sj.onc.1209881.","journal-title":"Oncogene"},{"key":"2158_CR7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5694\/j.1326-5377.1998.tb123335.x","volume":"168","author":"C Smith","year":"1998","unstructured":"Smith C, Kricker A, Armstrong B: Breast cancer mortality trends in Australia: 1921 to 1994. Med J Australia. 1998, 168: 11-14.","journal-title":"Med J Australia"},{"issue":"Suppl 2","key":"2158_CR8","first-page":"A63","volume":"3","author":"C Lean","year":"2007","unstructured":"Lean C, Bullivant C, Pagnini D, Tracey E, Hepburn A, Sinclair S, Bishop J: Review of cancer genetics services. Asia Pacific J Clin Oncol. 2007, 3 (Suppl 2): A63-","journal-title":"Asia Pacific J Clin Oncol"},{"key":"2158_CR9","unstructured":"Breast Cancer Incidence by Age; 2005. [ http:\/\/info.cancerresearchuk.org\/cancerstats\/types\/breast\/incidence\/ ]"},{"key":"2158_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1365-2753.2006.00657.x","volume":"13","author":"R Iredale","year":"2007","unstructured":"Iredale R, Elwyn G, Edwards A, Gray J: Attitudes of genetic clinicians in Wales to the future development of cancer genetics services. J Eval Clin Pract. 2007, 13: 86-89. 10.1111\/j.1365-2753.2006.00657.x.","journal-title":"J Eval Clin Pract"},{"key":"2158_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa070608","volume":"357","author":"G Rennert","year":"2007","unstructured":"Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA: Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations [see comment]. N Engl J Med. 2007, 357: 115-123. 10.1056\/NEJMoa070608.","journal-title":"N Engl J Med"},{"key":"2158_CR12","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1001\/archsurg.138.12.1323","volume":"138","author":"JN Weitzel","year":"2003","unstructured":"Weitzel JN, McCaffrey SM, Nedelcu R, MacDonald DJ, Blazer KR, Cullinane CA: Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg. 2003, 138: 1323-1328. 10.1001\/archsurg.138.12.1323. discussion 1329.","journal-title":"Arch Surg"},{"key":"2158_CR13","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1200\/JCO.2004.04.033","volume":"22","author":"K Metcalfe","year":"2004","unstructured":"Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, Narod SA: Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004, 22: 2328-2335. 10.1200\/JCO.2004.04.033.","journal-title":"J Clin Oncol"},{"key":"2158_CR14","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1200\/JCO.2005.02.7888","volume":"24","author":"LJ Pierce","year":"2006","unstructured":"Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, Harris EE, Gaffney DK, Haffty BG, Dawson LA, Narod SA, Olivotto IA, Eisen A, Whelan TJ, Olopade OI, Isaacs C, Merajver SD, Wong JS, Garber JE, Weber BL: Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1\/2-associated stage I\/II breast cancer [see comment]. J Clin Oncol. 2006, 24: 2437-2443. 10.1200\/JCO.2005.02.7888.","journal-title":"J Clin Oncol"},{"key":"2158_CR15","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1200\/JCO.2005.10.080","volume":"23","author":"LJ Herrinton","year":"2005","unstructured":"Herrinton LJ, Barlow WE, Yu O, Geiger AM, Elmore JG, Barton MB, Harris EL, Rolnick S, Pardee R, Husson G, Macedo A, Fletcher SW: Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project [see comment]. J Clin Oncol. 2005, 23: 4275-4286. 10.1200\/JCO.2005.10.080.","journal-title":"J Clin Oncol"},{"key":"2158_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/sj.bjc.6602703","volume":"93","author":"TC van Sprundel","year":"2005","unstructured":"van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, van Asperen CJ, Rutgers EJ, Van't Veer LJ, Tollenaar RA: Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005, 93: 287-292. 10.1038\/sj.bjc.6602703.","journal-title":"Br J Cancer"},{"key":"2158_CR17","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1200\/JCO.2001.19.19.3938","volume":"19","author":"SK McDonnell","year":"2001","unstructured":"McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, Frost MH, Johnson JL, Sitta DL, Slezak JM, Crotty TB, Jenkins RB, Sellers TA, Hartmann LC: Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001, 19: 3938-3943.","journal-title":"J Clin Oncol"},{"key":"2158_CR18","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1245\/s10434-007-9449-x","volume":"14","author":"BA Heemskerk-Gerritsen","year":"2007","unstructured":"Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Tan M, Meijers-Heijboer HE, Klijn JG, Seynaeve C: Prophylactic mastectomy in BRCA1\/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic [see comment]. Ann Surg Oncol. 2007, 14: 3335-3344. 10.1245\/s10434-007-9449-x.","journal-title":"Ann Surg Oncol"},{"key":"2158_CR19","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1002\/cncr.20617","volume":"101","author":"K Goldflam","year":"2004","unstructured":"Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM, Babiera GV, Ames FC, Ross MI, Feig BW, Sahin AA, Arun B, Meric-Bernstam F: Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004, 101: 1977-1986. 10.1002\/cncr.20617.","journal-title":"Cancer"},{"key":"2158_CR20","doi-asserted-by":"publisher","first-page":"R175","DOI":"10.1186\/bcr632","volume":"5","author":"N Loman","year":"2003","unstructured":"Loman N, Bladstrom A, Johannsson O, Borg A, Olsson H: Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Res. 2003, 5: R175-R186. 10.1186\/bcr632.","journal-title":"Breast Cancer Res"},{"key":"2158_CR21","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1055-9965.EPI-03-0545","volume":"14","author":"MD Schwartz","year":"2005","unstructured":"Schwartz MD, Lerman C, Brogan B, Peshkin BN, Isaacs C, DeMarco T, Halbert CH, Pennanen M, Finch C: Utilization of BRCA1\/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2005, 14: 1003-1007. 10.1158\/1055-9965.EPI-03-0545.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2158_CR22","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1200\/JCO.2007.12.3141","volume":"25","author":"TM Tuttle","year":"2007","unstructured":"Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA: Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007, 25: 5203-5209. 10.1200\/JCO.2007.12.3141.","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"2158_CR23","doi-asserted-by":"crossref","first-page":"abstract 509","DOI":"10.1200\/jco.2008.26.15_suppl.509","volume":"26","author":"R Katipamula","year":"2008","unstructured":"Katipamula R, Hoskin TL, Boughey JC, Degnim AC, Grant CS, Brandt KR, Loprinzi CL, Pruthi S, MP G: Trends in mastectomy rates at the Mayo Clinic Rochester: Effect of surgical year and preoperative MRI. J Clin Oncol. 2008, 26 (Suppl): abstract 509-","journal-title":"J Clin Oncol"},{"key":"2158_CR24","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.ejso.2005.05.007","volume":"31","author":"DG Evans","year":"2005","unstructured":"Evans DG, Lalloo F, Hopwood P, Maurice A, Baildam A, Brain A, Barr L, Howell A: Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. Eur J Surg Oncol. 2005, 31: 1112-1118. 10.1016\/j.ejso.2005.05.007.","journal-title":"Eur J Surg Oncol"},{"key":"2158_CR25","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1200\/JCO.2003.09.052","volume":"21","author":"H Meijers-Heijboer","year":"2003","unstructured":"Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, Ouweland van den AW, van Geel B, Klijn JG: Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2003, 21: 1675-1681. 10.1200\/JCO.2003.09.052.","journal-title":"J Clin Oncol"},{"key":"2158_CR26","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1200\/JCO.2004.04.086","volume":"22","author":"M Schwartz","year":"2004","unstructured":"Schwartz M, Lerman C, Brogan B, Peshkin B, Hughes Halbert C, DeMarco T, Lawrence W, Main D, Finch C, Magnant C, Pennanen M, Tsangaris T, Willey S, Isaacs C: Impact of BRCA1\/2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol. 2004, 22: 1823-1829. 10.1200\/JCO.2004.04.086.","journal-title":"J Clin Oncol"},{"key":"2158_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/ajmg.1320560305","volume":"56","author":"DF Easton","year":"1995","unstructured":"Easton DF, Ford D, Bishop DT, the Breast Cancer Linkage Consortium: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet. 1995, 56: 265-271.","journal-title":"Am J Hum Genet"},{"key":"2158_CR28","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa020119","volume":"346","author":"ND Kauff","year":"2002","unstructured":"Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K, Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002, 346: 1609-1615. 10.1056\/NEJMoa020119.","journal-title":"N Engl J Med"},{"key":"2158_CR29","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1056\/NEJMoa012158","volume":"346","author":"TR Rebbeck","year":"2002","unstructured":"Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL, For the Prevention and Observation of Surgical End Points Study Group: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002, 346: 1616-1622. 10.1056\/NEJMoa012158.","journal-title":"N Engl J Med"},{"key":"2158_CR30","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1093\/jnci\/91.17.1475","volume":"91","author":"TR Rebbeck","year":"1999","unstructured":"Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L: Breast cancer risk after prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999, 91: 1475-1479. 10.1093\/jnci\/91.17.1475.","journal-title":"J Natl Cancer Inst"},{"key":"2158_CR31","doi-asserted-by":"publisher","first-page":"7491","DOI":"10.1200\/JCO.2004.00.7138","volume":"23","author":"A Eisen","year":"2005","unstructured":"Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing C, Ainsworth P, Sun P, Narod SA: Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005, 23: 7491-7496. 10.1200\/JCO.2004.00.7138.","journal-title":"J Clin Oncol"},{"key":"2158_CR32","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(05)74803-0","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, Group AT: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer [see comment]. Lancet. 2005, 365: 60-62. 10.1016\/S0140-6736(05)74803-0.","journal-title":"Lancet"},{"key":"2158_CR33","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1056\/NEJMoa052258","volume":"353","author":"The Breast International Group (BIG) 1\u201398 Collaborative Group","year":"2005","unstructured":"The Breast International Group (BIG) 1\u201398 Collaborative Group: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005, 353: 2747-2757. 10.1056\/NEJMoa052258.","journal-title":"N Engl J Med"},{"key":"2158_CR34","doi-asserted-by":"publisher","first-page":"7413","DOI":"10.1158\/1078-0432.CCR-07-1083","volume":"13","author":"JE Quinn","year":"2007","unstructured":"Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK, Mullan PB, Johnston PG, Wilson RH, Harkin DP, Quinn JE: BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy [see comment]. Clin Canc Res. 2007, 13: 7413-7420. 10.1158\/1078-0432.CCR-07-1083.","journal-title":"Clin Canc Res"},{"key":"2158_CR35","doi-asserted-by":"publisher","first-page":"12117","DOI":"10.1073\/pnas.0702955104","volume":"104","author":"S Rottenberg","year":"2007","unstructured":"Rottenberg S, Nygren AO, Pajic M, van Leeuwen FW, Heijden van der I, Wetering van de K, Liu X, de Visser KE, Gilhuijs KG, van Tellingen O, Schouten JP, Jonkers J, Borst P: Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA. 2007, 104: 12117-12122. 10.1073\/pnas.0702955104.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2158_CR36","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/ijc.22789","volume":"121","author":"P Moller","year":"2007","unstructured":"Moller P, Evans D, Reis M, Gregory H, Anderson E, Maehle L, F L, Howell A, J A, Clark N, Lucassen A, Steel C: Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer. 2007, 121: 1017-1020. 10.1002\/ijc.22789.","journal-title":"Int J Cancer"},{"key":"2158_CR37","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.humpath.2007.10.011","volume":"39","author":"E Rakha","year":"2008","unstructured":"Rakha E, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, Ellis I: Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol. 2008, 39: 857-865. 10.1016\/j.humpath.2007.10.011.","journal-title":"Hum Pathol"},{"key":"2158_CR38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.7150\/ijms.3.117","volume":"3","author":"J De Soto","year":"2006","unstructured":"De Soto J, Deng C: PARP-inhibitors: Are they the long-sought genetically specific drugs for BRCA1\/2 associated breast cancers?. Int J Med Sci. 2006, 3: 117-123.","journal-title":"Int J Med Sci"},{"key":"2158_CR39","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T, Santarosa M, Dillon K, Hickson I, Knights C, Martin N, Jackson S, Smith G, Ashworth A: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005, 434: 917-920. 10.1038\/nature03445.","journal-title":"Nature"},{"key":"2158_CR40","unstructured":"ClinicalTrials.gov. [ http:\/\/www.clinicaltrials.gov ]"},{"key":"2158_CR41","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1200\/JCO.2008.17.8954","volume":"26","author":"P Fong","year":"2008","unstructured":"Fong P, Boss DS, Carden CP, Roelvink M, de Greve J, Gourley C, Carmichael J, de Bono JS, Schellens JH, Kaye SB: AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study [abstract]. J Clin Oncol. 2008, 26: 5510-10.1200\/JCO.2008.17.8954.","journal-title":"J Clin Oncol"},{"key":"2158_CR42","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nrc2054","volume":"7","author":"J Fackenthal","year":"2007","unstructured":"Fackenthal J, Olopade O: Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer. 2007, 7: 937-948. 10.1038\/nrc2054.","journal-title":"Nat Rev Cancer"},{"key":"2158_CR43","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/jnci\/93.16.1215","volume":"93","author":"N Loman","year":"2001","unstructured":"Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A: Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset cancer. J Nat Cancer Inst. 2001, 93: 1215-1223. 10.1093\/jnci\/93.16.1215.","journal-title":"J Nat Cancer Inst"},{"key":"2158_CR44","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P","volume":"88","author":"K Malone","year":"2000","unstructured":"Malone K, Daling J, Neal C, Suter N, O'Brien C, Cushing-Haugen K, Jonasdottir T, Thompson J, Ostra E: Frequency of BRCA1\/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer. 2000, 88: 1393-1402. 10.1002\/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P.","journal-title":"Cancer"},{"key":"2158_CR45","volume-title":"Current Best Advice About Familial Aspects of Breast\/ovarian Cancer","author":"National Breast Cancer Centre","year":"2000","unstructured":"National Breast Cancer Centre: Current Best Advice About Familial Aspects of Breast\/ovarian Cancer. 2000, Sydney: NHMRC National Breast Cancer Centre"},{"key":"2158_CR46","volume-title":"Clinical Guidelines Evidence Review for The Classification Care of Women at Risk of Familial Breast Cancer","author":"A McIntosh","year":"2004","unstructured":"McIntosh A, Shaw C, Evans G, Turnbull N, Bahar N, Barclay M, Easton D, Emery J, Gray J, Halpin J, Hopwood P, McKay J, Sheppard C, Sibbering M, Watson M, Wailoo A, Hutchinson A: Clinical Guidelines Evidence Review for The Classification Care of Women at Risk of Familial Breast Cancer. 2004, London: National Collaborating Centre for Primary Care, University of Sheffield"},{"key":"2158_CR47","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S0140-6736(03)12856-5","volume":"361","author":"F Lalloo","year":"2003","unstructured":"Lalloo F, Varley J, Ellis D, Moran A, O'Dair L, Pharaoh P, Evans D, the Early Onset Breast Cancer Group: Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet. 2003, 361: 1101-10.1016\/S0140-6736(03)12856-5.","journal-title":"Lancet"},{"key":"2158_CR48","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/JCO.2004.04.179","volume":"22","author":"D Choi","year":"2004","unstructured":"Choi D, Lee M, Bale A, Carter D, Haffty B: Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol. 2004, 22: 1638-1645. 10.1200\/JCO.2004.04.179.","journal-title":"J Clin Oncol"},{"key":"2158_CR49","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.ejca.2007.04.023","volume":"43","author":"P Moller","year":"2007","unstructured":"Moller P, Hagen A, Apold J, Maehle L, Clark N, Fiane B, Lovslett K, Hovig E, Vabo A: Genetic epidemiology of BRCA mutations \u2013 family history detects less than 50% of the mutation carriers. Eur J Cancer. 2007, 43: 1713-1717. 10.1016\/j.ejca.2007.04.023.","journal-title":"Eur J Cancer"},{"key":"2158_CR50","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/sj.ejhg.5201806","volume":"15","author":"A Gerhardus","year":"2007","unstructured":"Gerhardus A, Schleberger H, Schlegelberger B, Gadzicki D: Diagnostic accuracy of methods for the detection of BRCA1 and RBC2 mutations: A systematic review. Eur J Hum Genet. 2007, 15: 619-627. 10.1038\/sj.ejhg.5201806.","journal-title":"Eur J Hum Genet"},{"key":"2158_CR51","first-page":"741","volume":"8","author":"JL Hopper","year":"1999","unstructured":"Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, Easton DF, Venter DJ: Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev. 1999, 8: 741-747.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2158_CR52","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1399-0004.2007.00747.x","volume":"71","author":"M Loizidou","year":"2007","unstructured":"Loizidou M, Marcou Y, Anastasiadou V, Newbold R, Hadjisavvas A, Kyriacou K: Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus. Clin Genet. 2007, 71: 165-170. 10.1111\/j.1399-0004.2007.00747.x.","journal-title":"Clin Genet"},{"key":"2158_CR53","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/humu.9188","volume":"22","author":"J Mart\u00ednez-Ferrandis","year":"2003","unstructured":"Mart\u00ednez-Ferrandis J, Vega A, Chirivella I, Mar\u00edn-Garc\u00eda P, Insa A, Lluch A, Carracedo A, Chaves F, Garc\u00eda-Conde J, Cervantes A, Armengod M: Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early-onset breast cancer: Identification of three novel pathogenic mutations. Hum Mutat. 2003, 22: 417-418. 10.1002\/humu.9188.","journal-title":"Hum Mutat"},{"key":"2158_CR54","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","volume":"20","author":"SR Lakhani","year":"2002","unstructured":"Lakhani SR, Vijver Van De MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2 [see comment]. J Clin Oncol. 2002, 20: 2310-2318. 10.1200\/JCO.2002.09.023.","journal-title":"J Clin Oncol"},{"key":"2158_CR55","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","volume":"26","author":"D Atchley","year":"2008","unstructured":"Atchley D, Albarracin C, Lopez A, Valero V, Amos C, Gonzalez-Angulo A, Hortobagyi G, Arun B: Clinical and pathological characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008, 26: 4282-4288. 10.1200\/JCO.2008.16.6231.","journal-title":"J Clin Oncol"},{"key":"2158_CR56","first-page":"505","volume":"60","author":"D Abeliovich","year":"1997","unstructured":"Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T: The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet. 1997, 60: 505-514.","journal-title":"Am J Hum Genet"},{"key":"2158_CR57","unstructured":"BRCA Risk Calculator and Mutation Prevalence Tables. [ http:\/\/www.myriadtests.com\/provider\/brca-mutation-prevalence.htm ]"},{"key":"2158_CR58","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1075-122X.2004.21543.x","volume":"10","author":"AJ Stolier","year":"2004","unstructured":"Stolier AJ, Fuhrman GM, Mauterer L, Bolton JS, Superneau DW: Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation [see comment]. Breast J. 2004, 10: 475-480. 10.1111\/j.1075-122X.2004.21543.x.","journal-title":"Breast J"},{"key":"2158_CR59","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.ejca.2005.02.030","volume":"41","author":"CC Warlam-Rodenhuis","year":"2005","unstructured":"Warlam-Rodenhuis CC, Koot VC, Luijt van der RB, Vasen HF, Ausems MG: A prospective study on predictive factors linked to the presence of BRCA1 and BRCA2 mutations in breast cancer patients. Eur J Cancer. 2005, 41: 1409-1415. 10.1016\/j.ejca.2005.02.030.","journal-title":"Eur J Cancer"},{"key":"2158_CR60","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1016\/j.ejca.2006.05.032","volume":"42","author":"KJ Schlich-Bakker","year":"2006","unstructured":"Schlich-Bakker KJ, Warlam-Rodenhuis CC, van Echtelt J, Bout van den J, Ausems MG, ten Kroode HF: Short term psychological distress in patients actively approached for genetic counselling after diagnosis of breast cancer. Eur J Cancer. 2006, 42: 2722-2728. 10.1016\/j.ejca.2006.05.032.","journal-title":"Eur J Cancer"},{"key":"2158_CR61","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/pon.933","volume":"14","author":"B Meiser","year":"2005","unstructured":"Meiser B: Psychological impact of genetic testing for cancer susceptibility: An update of the literature. Psychooncology. 2005, 14: 1060-1074. 10.1002\/pon.933.","journal-title":"Psychooncology"},{"key":"2158_CR62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1023\/B:FAME.0000026820.32469.4a","volume":"3","author":"JG Reichelt","year":"2004","unstructured":"Reichelt JG, Heimdal K, Moller P, Dahl AA: BRCA1 testing with definitive results: A prospective study of psychological distress in a large clinic-based sample. Fam Cancer. 2004, 3: 21-28. 10.1023\/B:FAME.0000026820.32469.4a.","journal-title":"Fam Cancer"},{"key":"2158_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/109065704323015987","volume":"8","author":"S Loader","year":"2004","unstructured":"Loader S, Shields CG, Rowley PT: Impact of genetic testing for breast-ovarian cancer susceptibility. Genet Test. 2004, 8: 1-12. 10.1089\/109065704323015987.","journal-title":"Genet Test"},{"key":"2158_CR64","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/ajmg.a.20374","volume":"124","author":"MS van Roosmalen","year":"2004","unstructured":"van Roosmalen MS, Stalmeier PF, Verhoef LC, Hoekstra-Weebers JE, Oosterwijk JC, Hoogerbrugge N, Moog U, van Daal WA: Impact of BRCA1\/2 testing and disclosure of a positive test result on women affected and unaffected with breast or ovarian cancer. Am J Med Genet A. 2004, 124: 346-355. 10.1002\/ajmg.a.20374.","journal-title":"Am J Med Genet A"},{"key":"2158_CR65","first-page":"97","volume":"11","author":"V Bonadona","year":"2002","unstructured":"Bonadona V, Saltel P, Desseigne F, Mignotte H, Saurin JC, Wang Q, Sinilnikova O, Giraud S, Freyer G, Plauchu H, Puisieux A, Lasset C, Bonadona V, Saltel P, Desseigne F, Mignotte H, Saurin J-C, Wang Q, Sinilnikova O, Giraud S, Freyer G, Plauchu H, Puisieux A, Lasset C: Cancer patients who experienced diagnostic genetic testing for cancer susceptibility: reactions and behavior after the disclosure of a positive test result. Cancer Epidemiol Biomarkers Prev. 2002, 11: 97-104.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2158_CR66","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10549-006-9423-5","volume":"104","author":"K Graves","year":"2007","unstructured":"Graves K, Peshkin B, Halbert C, DeMarco T, Isaacs C, Schwartz M: Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors. Breast Cancer Res Tr. 2007, 104: 321-329. 10.1007\/s10549-006-9423-5.","journal-title":"Breast Cancer Res Tr"},{"key":"2158_CR67","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.2006.07.3890","volume":"25","author":"KP Tercyak","year":"2007","unstructured":"Tercyak KP, Peshkin BN, Brogan BM, DeMarco T, Pennanen MF, Willey SC, Magnant CM, Rogers S, Isaacs C, Schwartz MD: Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1\/2 gene testing. J Clin Oncol. 2007, 25: 285-291. 10.1200\/JCO.2006.07.3890.","journal-title":"J Clin Oncol"},{"key":"2158_CR68","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1200\/JCO.2007.12.6078","volume":"26","author":"KA Metcalfe","year":"2008","unstructured":"Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD, Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manoukian S, Moller P, Weitzel J, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study G: Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008, 26: 1093-1097. 10.1200\/JCO.2007.12.6078.","journal-title":"J Clin Oncol"},{"key":"2158_CR69","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1200\/JCO.2004.02.994","volume":"22","author":"MB Daly","year":"2004","unstructured":"Daly MB: Tailoring breast cancer treatment to genetic status: the challenges ahead [comment]. J Clin Oncol. 2004, 22: 1776-1777. 10.1200\/JCO.2004.02.994.","journal-title":"J Clin Oncol"},{"key":"2158_CR70","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10549-007-9680-y","volume":"109","author":"K Schlich-Bakker","year":"2008","unstructured":"Schlich-Bakker K, Ausems ME, Schipper M, Ten Kroode H, Warlam-Rodenhuis C, van Den Bout J: BRCA1\/2 mutation testing in breast cancer patients: a prospective study of the long-term psychological impact of approach during adjuvant radiotherapy. Breast Cancer Res Treat. 2008, 109: 507-514. 10.1007\/s10549-007-9680-y.","journal-title":"Breast Cancer Res Treat"},{"key":"2158_CR71","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/GIM.0b013e318159a318","volume":"11","author":"K Schlich-Bakker","year":"2007","unstructured":"Schlich-Bakker K, Ten Kroode H, Warlam-Rodenhuis C, van Den Bout J, Ausems M: Barriers to participating in genetic counselling and BRCA testing during primary treatment for breast cancer. Genet Med. 2007, 11: 766-777.","journal-title":"Genet Med"},{"key":"2158_CR72","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1365-2354.2005.00574.x","volume":"14","author":"A Ardern-Jones","year":"2005","unstructured":"Ardern-Jones A, Kenen R, Eeles R: Too much too soon? Patients' and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. Eur J Cancer Care (Engl.). 2005, 14: 272-281. 10.1111\/j.1365-2354.2005.00574.x.","journal-title":"Eur J Cancer Care (Engl.)"},{"issue":"Suppl 2","key":"2158_CR73","first-page":"437","volume":"16","author":"E Lobb","year":"2008","unstructured":"Lobb E, Hallowell N, Barlow-Stewart K, Suthers G: Determining the genetic status of women newly diagnosed with breast cancer prior to treatment decision: An ethical challenge. Eur J Hum Genet. 2008, 16 (Suppl 2): 437-","journal-title":"Eur J Hum Genet"},{"key":"2158_CR74","first-page":"CD001431","volume-title":"Cochrane Database Syst Rev","author":"A O'Connor","year":"2001","unstructured":"O'Connor A, Stacey D, Rovner D, Holmes-Rovner M, Tetroe J, Llewellyn-Thomas H, Entwistle V, Rostom A, Fiset V, Barry M, Jones J: Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2001, CD001431-"},{"key":"2158_CR75","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10897-006-9023-x","volume":"15","author":"EA Lobb","year":"2006","unstructured":"Lobb EA, Butow PN, Moore A, Barratt A, Tucker K, Gaff C, Kirk J, Dudding T, Butt D: Development of a communication aid to facilitate risk communication in consultations with unaffected women from high risk breast cancer families: a pilot study. J Genet Couns. 2006, 15: 393-405. 10.1007\/s10897-006-9023-x.","journal-title":"J Genet Couns"},{"key":"2158_CR76","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/pon.1353","volume":"17","author":"C Wakefield","year":"2008","unstructured":"Wakefield C, Meiser B, Homewood J, Taylor A, Gleeson M, Williams R, Tucker K, the AGenDA Collaborative Group: A randomized trial of a breast\/ovarian cancer genetic testing decision aid used as a communication aid during genetic counseling. Psychooncology. 2008, 17: 844-854. 10.1002\/pon.1353.","journal-title":"Psychooncology"},{"key":"2158_CR77","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10549-007-9539-2","volume":"107","author":"C Wakefield","year":"2008","unstructured":"Wakefield C, Meiser B, Homewood J, Peate M, Taylor A, Lobb E, Kirk J, Young M, Williams R, Dudding T, Tucker K, the AGenDA Collaborative Group: A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk. Breast Cancer Res Treat. 2008, 107: 289-301. 10.1007\/s10549-007-9539-2.","journal-title":"Breast Cancer Res Treat"},{"key":"2158_CR78","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7150\/ijms.5.197","volume":"5","author":"N Uhrhammer","year":"2008","unstructured":"Uhrhammer N, Abdelouahab A, Lafarge L, Feillel V, Dib A, Bignon Y: BRCA1 mutations in Algerian breast cancer patients: High frequency in young, sporadic cases. Int J Med Sci. 2008, 5: 197-202.","journal-title":"Int J Med Sci"},{"key":"2158_CR79","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/jmg.2005.034744","volume":"43","author":"B Haffty","year":"2006","unstructured":"Haffty B, Silber A, Matloff E, Chung J, Lannin D: Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women. J Med Genet. 2006, 43: 133-137. 10.1136\/jmg.2005.034744.","journal-title":"J Med Genet"},{"key":"2158_CR80","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/sj.ejhg.5200988","volume":"11","author":"U Hamann","year":"2003","unstructured":"Hamann U, Liu X, Bungardt N, Ulmer HU, Bastert G, Sinn H-P: Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany. Eur J Hum Genet. 2003, 11: 464-467. 10.1038\/sj.ejhg.5200988.","journal-title":"Eur J Hum Genet"},{"key":"2158_CR81","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/gcc.20199","volume":"43","author":"V Bonadona","year":"2005","unstructured":"Bonadona V, Sinilnikova OM, Chopin S, Antoniou AC, Mignotte H, Mathevet P, Br\u00e9mond A, Martin A, Bobin JY, Romestaing P, Raudrant D, Rudigoz RC, L\u00e9on\u00e9 M, Chauvin F, Easton DF, Lenoir GM, Lasset C: Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: Results from a prospective population-based study in France. Genes Chromosomes Cancer. 2005, 43: 404-413. 10.1002\/gcc.20199.","journal-title":"Genes Chromosomes Cancer"},{"key":"2158_CR82","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ijc.11271","volume":"106","author":"S de Sanjose","year":"2003","unstructured":"de Sanjose S, Leone M, Berez V, Izquierdo A, Font R, Brunet J, Louat T, Vilardell L, Borras J, Viladiu P, Bosch F, Lenoir G, Sinilnikova O: Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. Int J Cancer. 2003, 106: 588-593. 10.1002\/ijc.11271.","journal-title":"Int J Cancer"},{"key":"2158_CR83","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jama.279.12.922","volume":"279","author":"KE Malone","year":"1998","unstructured":"Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV, Ostrander EA: BRCA1 mutations and breast cancer in the general population: Analyses in women before age 35 years and in women before age 45 years with first-degree family history [see comment]. JAMA. 1998, 279: 922-929. 10.1001\/jama.279.12.922.","journal-title":"JAMA"},{"key":"2158_CR84","doi-asserted-by":"publisher","first-page":"E17","DOI":"10.1136\/jmg.37.9.e17","volume":"37","author":"J Plaschke","year":"2000","unstructured":"Plaschke J, Commer T, Jacobi C, Schackert HK, Chang-Claude J: BRCA2 germline mutations among early onset breast cancer patients unselected for family history of the disease. J Med Genet. 2000, 37: E17-10.1136\/jmg.37.9.e17.","journal-title":"J Med Genet"},{"key":"2158_CR85","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/1097-0142(20000815)89:4<811::AID-CNCR13>3.0.CO;2-R","volume":"89","author":"GH Ho","year":"2000","unstructured":"Ho GH, Phang BH, Ng IS, Law HY, Soo KC, Ng EH: Novel germline BRCA1 mutations detected in women in singapore who developed breast carcinoma before the age of 36 years. Cancer. 2000, 89: 811-816. 10.1002\/1097-0142(20000815)89:4<811::AID-CNCR13>3.0.CO;2-R.","journal-title":"Cancer"},{"key":"2158_CR86","doi-asserted-by":"publisher","first-page":"R6","DOI":"10.1186\/bcr443","volume":"4","author":"V Yassaee","year":"2002","unstructured":"Yassaee V, Zeinali S, Harirchi I, Jarvandi J, Mohagheghi M, Hornby D, Dalton A: Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer. Breast Cancer Res. 2002, 4: R6-10.1186\/bcr443.","journal-title":"Breast Cancer Res"},{"key":"2158_CR87","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1054\/bjoc.2000.1407","volume":"83","author":"Anglican Breast Cancer Study Group","year":"2000","unstructured":"Anglican Breast Cancer Study Group: Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglican Breast Cancer Study Group. Br J Cancer. 2000, 83: 1301-1308. 10.1054\/bjoc.2000.1407.","journal-title":"Br J Cancer"},{"key":"2158_CR88","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/sj.bjc.6690008","volume":"79","author":"M Southey","year":"1999","unstructured":"Southey M, Tesoriero A, Andersen C, Jennings K, Brown S, Dite G, Jenkins M, Osborne R, Maskiell J, Porter L, Giles G, McCredie M, Hopper J, Vent D: BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. Br J Cancer. 1999, 79: 34-39. 10.1038\/sj.bjc.6690008.","journal-title":"Br J Cancer"},{"key":"2158_CR89","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJM199705153362003","volume":"336","author":"M Krainer","year":"1997","unstructured":"Krainer M, Silva-Arrieta S, FitzGerald MG, Shimada A, Ishioka C, Kanamaru R, MacDonald DJ, Unsal H, Finkelstein DM, Bowcock A, Isselbacher KJ, Haber DA: Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer [see comment]. N Engl J Med. 1997, 336: 1416-1421. 10.1056\/NEJM199705153362003.","journal-title":"N Engl J Med"},{"key":"2158_CR90","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/jnci\/91.11.943","volume":"91","author":"J Peto","year":"1999","unstructured":"Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer [see comment]. J Natl Cancer I. 1999, 91: 904-905. 10.1093\/jnci\/91.11.943.","journal-title":"J Natl Cancer I"},{"key":"2158_CR91","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10549-006-9182-3","volume":"99","author":"J Lubinski","year":"2006","unstructured":"Lubinski J, Gorski B, Huzarski T, Byrski T, Gronwald J, J S-Fn, Domagala W, Chosia M, Ucinski M, Grzybowska E, Lange D, Maka B, Mackiewicz A, Karczewska A, Breborowicz J, Lamperska K, Stawicka M, Gozdecka-Grodecka S, Bebenek M, Sorokin D, Wojnar A, Haus O, Sir J, Mierzwa T, Niepsuj S, Gugala K, Gozdz S, Sygut J, Kozak-Klonowska B, Musiatowicz B, et al: BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat. 2006, 99: 71-76. 10.1007\/s10549-006-9182-3.","journal-title":"Breast Cancer Res Treat"},{"key":"2158_CR92","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.1998.16.5.1642","volume":"16","author":"M Robson","year":"1998","unstructured":"Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan R, Hirschaut Y, Pressman P, Rosen P, Lesser M, Norton L, Offit K: BRCA-associated breast cancer in young women. J Clin Oncol. 1998, 16: 1642-1649.","journal-title":"J Clin Oncol"},{"key":"2158_CR93","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0959-8049(00)00045-9","volume":"36","author":"R Gershoni-Baruch","year":"2000","unstructured":"Gershoni-Baruch R, Dagan E, Fried G, Bruchim Bar-Sade R, Sverdlov-Shiri R, Zelicksson G, Friedman E: Significantly lower rates of BRCA1\/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer. Eur J Cancer. 2000, 36: 983-986. 10.1016\/S0959-8049(00)00045-9.","journal-title":"Eur J Cancer"},{"key":"2158_CR94","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/1097-0215(20010520)95:3<189::AID-IJC1032>3.0.CO;2-N","volume":"20","author":"P Tonin","year":"2001","unstructured":"Tonin P, Perret C, Lambert J, Paradis A, Kantemiroff T, Beno\u00eet M, Martin G, Foulkes W, Ghadirian P: Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history. Int J Cancer. 2001, 20: 189-193. 10.1002\/1097-0215(20010520)95:3<189::AID-IJC1032>3.0.CO;2-N.","journal-title":"Int J Cancer"},{"key":"2158_CR95","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.ejca.2005.11.032","volume":"42","author":"F Lalloo","year":"2006","unstructured":"Lalloo F, Varley J, Moran A, Ellis D, O'Dair L, Pharaoh P, Antoniou A, Hartley R, Shenton A, Seal S, Bulman B, Howell A, Evans D: BRCA1, BRCA2 and T53 mutations in very early-onset breast cancer with asociated risks for relatives. Eur J Cancer. 2006, 42: 1143-1150. 10.1016\/j.ejca.2005.11.032.","journal-title":"Eur J Cancer"},{"key":"2158_CR96","volume-title":"Advice About Familial Aspects of Breast Cancer and Epithelial Ovarian Cancer: A Guide for Health Professionals","author":"National Breast Cancer Centre","year":"2006","unstructured":"National Breast Cancer Centre: Advice About Familial Aspects of Breast Cancer and Epithelial Ovarian Cancer: A Guide for Health Professionals. 2006, Sydney: NHMRC National Breast Cancer Centre"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr2194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/bcr2194\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr2194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:22:47Z","timestamp":1557966167000},"score":1,"resource":{"primary":{"URL":"http:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/bcr2194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,28]]},"references-count":96,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["2158"],"URL":"https:\/\/doi.org\/10.1186\/bcr2194","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,28]]},"article-number":"216"}}